Psoriasis patients who are homozygous for the HLA-Cw*0602 allele have a 2.5-fold increased risk of developing psoriasis compared with Cw6 heterozygotes
Psoriasis patients who are homozygous for the HLA-Cw*0602 allele have a 2.5-fold increased risk of developing psoriasis compared with Cw6 heterozygotes
复制标题
DOI：
10.1046/j.1365-2133.2003.05115.x
复制
发表时间：
2003-02-01
影响因子：
10.3
通讯作者：
Valdimarsson, H
中科院分区：
文献类型：
--
作者：
Gudjonsson, JE;Karason, A;Valdimarsson, H
银屑病与某些人类白细胞相关抗原密切相关，特别是HLA-Cw*0602。据报道，HLA-Cw*0602阳性的患者比hla - cw6阴性的患者有更多的活动性疾病和更年轻的发病年龄。目的探讨HLA-Cw*0602纯合子与杂合子银屑病患者的临床特征及相对危险度是否存在差异。方法对106例慢性斑块型银屑病患者进行临床评价和HLA-C分型。此外，对512例不相关对照进行HLA-C分型。结果HLA-Cw*0602阳性646例（64.2%），纯合子68例（6.8%）。杂合子与发生银屑病的相对风险相关，为8.9，而Cw6纯合子患者的相对风险为23.1。纯合子患者的发病时间也更早（平均15.0年对17.8年，P=0.04）。然而，Cw6纯合子与杂合子在疾病严重程度、发作、斑块分布、指甲变化或任何其他临床参数记录方面没有差异。结论该基因在主要组织相容性复合体区域的纯合性对银屑病发病风险和发病早期有主要的累加性影响，但对银屑病的表型或严重程度无显著影响。
Background Psoriasis is strongly associated with certain human leucocyte-associated antigens, especially HLA-Cw*0602. Patients who are HLA-Cw*0602 positive have been reported to have more active disease and a younger age at disease onset than HLA-Cw6-negative patients.Objectives To ascertain whether there are differences in the clinical features and relative risk between HLA-Cw*0602 homozygous and heterozygous psoriasis patients.Methods One thousand and six patients with chronic plaque psoriasis were evaluated clinically and HLA-C typed. In addition, 512 unrelated controls were typed for HLA-C.Results Of the patients 646 (64.2%) were HLA-Cw*0602 positive, and 68 (6.8%) were homozygous for this allele. Heterozygosity was associated with a relative risk of developing psoriasis of 8.9 compared with 23.1 for the Cw6 homozygous patients. The homozygous patients also had an earlier disease onset (mean 15.0 vs. 17.8 years, P=0.04). However, the Cw6 homozygotes did not differ from the heterozygotes with respect to disease severity, guttate onset, distribution of plaques, nail changes or any other clinical parameter recorded.Conclusions Homozygosity for the gene in the major histocompatibility complex region has a major additive impact on the risk of developing psoriasis and predisposes to an earlier disease onset, but does not have any marked influence on the phenotype or the severity of the disease.